Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gaboxadol - Lundbeck A/S

Next Previous
X
Search
Drug Profile

Gaboxadol - Lundbeck A/S

Alternative Names: LU-02030; LU-2-030; MK-0928; OV-101; THIP

Latest Information Update: 15 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Max Planck Institute of Psychiatry
  • Developer Lundbeck A/S; Ovid Therapeutics
  • Class Antidepressants; Antiepileptic drugs; Isoxazoles; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angelman syndrome; Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Angelman syndrome; Epilepsy; Fragile X syndrome; Insomnia; Major depressive disorder

Most Recent Events

  • 13 Mar 2023 Ovid Therapeutics plans a clinical trial (Combination therapy) for Fragile X syndrome in (Country) in 2023
  • 28 Feb 2023 Ovid Therapeutics amended the Healx License and Option Agreement by three months to extend the option period
  • 15 Mar 2022 Ovid Therapeutics has patents pending for manufacturing processes of gaboxadol

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top